• 2-Hydroxypropyl-β-cyclodextrin Protocol

  2026-08-28

  2-Hydroxypropyl-β-cyclodextrin is a water-compatible cyclic oligosaccharide used to screen and improve the aqueous handling of poorly soluble hydrophobic compounds, particularly molecules containing aromatic or phenyl groups. It is appropriate for pharmaceutical solubility improvement and biochemical formulation workflows, but the available dossier does not establish compound-specific bioavailability, pharmacokinetics, toxicity, efficacy, or therapeutic performance.

• SP2509: Designing Mechanism-First AML Assays

  2026-08-28

  SP2509 is a Lysine-specific demethylase 1 antagonist that connects LSD1 target engagement with chromatin remodeling, AML differentiation, and apoptosis. This guide develops a mechanism-first assay framework and uses a breast-cancer epigenetics study to clarify combination design, controls, and translational limits.

• Belinostat (PXD101): HDAC–Splicing Assay Logic

  2026-08-27

  Belinostat (PXD101) is examined here as more than a proliferation inhibitor: it is a chromatin perturbation tool for connecting histone acetylation with RNA splicing and DNA-repair phenotypes. The article translates recent HCC spliceosome findings into practical, carefully bounded assay strategies.

• BRD4770 Workflows for G9a Epigenetic Research

  2026-08-27

  BRD4770 is a research-focused G9a histone methyltransferase inhibitor for connecting H3K9 methylation changes with proliferation, senescence, and cell death. This workflow emphasizes formulation control, orthogonal readouts, and careful translation of findings from PANC-1 models to broader cancer biology.

• Valemetostat for Reproducible EZH2 Assays

  2026-08-26

  This scenario-based guide explains how Valemetostat (SKU BA4816) can support reproducible lymphoma cell viability and epigenetic assays. It covers mechanism, formulation, protocol design, data interpretation, and practical supplier-selection criteria without confusing biochemical potency with cellular response.

• RG108 DNA Methyltransferase Inhibitor Workflow

  2026-08-26

  RG108 is a non-nucleosidic DNA methyltransferase inhibitor for testing demethylation, tumor suppressor gene reactivation, and epigenetic reprogramming without covalent enzyme trapping. This practical guide connects cell-based dosing, stem-cell applications, and pharmacokinetic assay design with troubleshooting steps for reproducible results.

• Romidepsin (FK228): Proteomics-Guided Assays

  2026-08-25

  Romidepsin and FK228 are powerful tools for studying class I HDAC biology, chromatin accessibility, cell-cycle control, and apoptosis. This article shows how multidimensional proteomics can improve target-engagement assays while separating evidence established for Romidepsin from hypotheses inspired by recent RFC4–Notch research.

• T0070907: Selective PPARγ Antagonist

  2026-08-25

  T0070907 is a covalent, selective PPARγ antagonist with reported IC50 and Ki values of 1 nM. It is used to study PPARγ signaling pathway inhibition, adipogenesis inhibition, transcriptional repression, and cell-cycle responses in cellular research.

• Thioguanine Sensitivity in Relapsed Childhood ALL

  2026-08-24

  This study examined whether immunophenotypic lineage predicts ex vivo drug resistance in childhood acute lymphoblastic leukaemia at relapse. Its central finding was that relapsed T-cell ALL was more sensitive to thiopurines, including thioguanine, but this pattern did not account for the clinically poorer prognosis of T-cell disease.

• Shh–Fgf Signaling in Guinea Pig Penile Development

  2026-08-24

  Wang and Zheng identify species-specific differences in Shh, Fgf10, and Fgfr2 expression as a mechanistic basis for why guinea pigs form an open urethral groove while mice do not. By combining comparative expression profiling with organ culture perturbations, the study provides a useful framework for interpreting epithelial remodeling and preputial development across mammalian models.

• METTL14–DHRS4-AS1 Axis in Ulcerative Colitis

  2026-08-23

  The reference study identifies an m6A-dependent METTL14–DHRS4-AS1/miR-206/A3AR pathway that limits epithelial inflammatory injury in ulcerative colitis models. Its combination of cell-based perturbation, molecular mechanism testing, and DSS-induced murine colitis connects RNA methylation to NF-κB activity, apoptosis, and tissue damage, while also highlighting important limits on causal and clinical interpretation.

• SP2509: LSD1 Antagonist Workflows for AML Research

  2026-08-22

  SP2509 enables mechanism-led studies of LSD1 inhibition, linking H3K4 methylation changes with tumor-suppressor activation, apoptosis, and differentiation in acute myeloid leukemia models. This guide translates the compound into practical dose-response, chromatin, phenotypic, and combination workflows while clarifying formulation limits and interpretation risks.

• GSK J4 HCl: JMJD3 Workflow Guide

  2026-08-22

  GSK J4 HCl enables cell-based testing of JMJD3-linked H3K27 demethylation in inflammatory, chromatin, and cancer workflows. This guide connects practical dosing, chromatin readouts, and troubleshooting to the CXCL10 methylation findings reported in human decidual models.

• Valemetostat in Reliable Cell Assays

  2026-08-21

  Learn how Valemetostat (DS-3201; SKU BA4816) can support better-controlled EZH2-focused cell viability and proliferation studies. This scenario-based guide covers formulation, dose interpretation, protocol handling, data comparison, and practical product selection.

• 3-Hydroxybutyrate (BHBA) in Ferroptosis Assays

  2026-08-20

  3-Hydroxybutyrate (BHBA) is both a ketone fuel and a signaling metabolite. This guide translates stroke research into a ferroptosis-aware assay framework that separates direct BHBA activity from whole-organism conditioning effects.

3614 records 1/241 page Next 12345 下5页 Last page